Current Neuro-Oncology
Volume
28 Number 9
31 March 2026
Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 9, 31 March
Woo PYM, Lee CKW, Li LF, Hui VKH, Chan DTM, Lee MWY, Chan TKT,
Wong DKK, Chow JSW, Ho JMK, Chow JKH, Tse TPK, Ko NMW, Cheung KM,
Leung AKC, Wong KCW, Loong HHF, Poon WS, El-Helali A.
Outcomes
of H3K27M-altered diffuse midline glioma adult Chinese patients
and real-world experience with German-sourced ONC201 targeted
therapy: A multi-center study in Hong Kong.
Neurooncol
Adv. 2026 Mar 21;8(1):vdag074. doi:
10.1093/noajnl/vdag074. PMID:
42011291. ˍ
Lockhart Z, Ruiz VY, King Z, Kirnaz S, Jabbar Dar A, Abbas I,
Oriko D, Cohen J, Loeb DM, Fox JL, Martin AM, Kobets AJ.
Treatment
strategies for relapsed medulloblastoma in the pediatric
population: illustrative case.
J
Neurosurg Case Lessons. 2026 Mar 23;11(12):CASE25612.
doi:
10.3171/CASE25612. PMID:
41871404. ˍ
Brentlinger MN, Patel J, Khan A, Castro-Echeverry E, Abdullaev Z,
Aldape K, Lehman NL.
Diffuse
pediatric-type high grade glioma, RTK1 subtype, subclass C with
SYN2::PPARG
fusion in an older adult.
CNS
Oncol. 2026 Mar 25;15(1):2641996. doi:
10.1080/20450907.2026.2641996. PMID:
41877551. ˍ
Attinà G, Maurizi P, Romano A, Talloa D, Verdolotti T,
Frassanito P, Tamburrini G, Chiesa S, Mastrangelo S, Ruggiero
A.
Concurrent chemoradiotherapy with
temozolomide in newly pediatric diffuse intrinsic pontine glioma:
clinical outcomes and safety analysis.
Transl
Pediatr. 2026 Mar 26;15(4):140. doi:
10.21037/tp-2025-1-942. PMID:
42158701. ˍ
Wright E, Billups C, Rush S, Li Y, Janns A, Michalski JM, Salloum
R, de Blank P.
Cumulative dose of
chemotherapy and survival outcomes in children with average risk
medulloblastoma treated on Children's Oncology Group study
ACNS0331.
Neuro
Oncol. 2026 Mar 26:noag064. doi:
10.1093/neuonc/noag064. PMID:
41885589. ˍ
Botti A, Sghedoni R, Orlandi M, Paolani G, Ciammella P,
Giaccherini L, Iotti C, Iori M.
A
Pipeline for MRI-Guided dose painting by number radiation Therapy:
GLIORAD - a phase I-II clinical trial in recurrent glioblastoma.
Phys
Med. 2026 Mar 27;145:105773. doi:
10.1016/j.ejmp.2026.105773. PMID:
41903279. Trial
registration ID: NCT04610229˰
ˍ
Liu H, Su Y, Zhang J, Chen X, Deng K, Chen L, Feng J, Wu X,
Daniels C, Li Y, Zhang J, Zhao Y, Shi Y, Liu F, Feng Z, Wang D,
Han D, Wang W, Wang M, Zhang J, Qi X, Li J, Gong J, Liu W, Tian Y,
Chen R, Jiang T, Taylor MD, Li C, Tian Y, Qiu X.
Long-term
outcomes by clinical and molecular risk stratification in patients
with medulloblastoma receiving risk-adapted therapy.
Med.
2026 Mar 27;7(5):101076. doi:
10.1016/j.medj.2026.101076. PMID:
41903543˰ ˍ
*Ahmadi M, Tanha AS, Elahifard H, Bahonar M, Askari E.
Incidental
Detection of Glioblastoma Multiforme With PSMA Uptake on Initial
Prostate Cancer Staging.
Clin
Nucl Med. 2026 Mar 31. doi:
10.1097/RLU.0000000000006451. PMID:
41950268˰ ˍ
*Shen Z, Hou Z, Han W, Zhang Y, Zhang W, Wu S, Liang J, Jiang C,
Wang Z, Wang W, Zhang S, Sakurai H, Shimizu Qingshui Xiangxing S.
Significance of Early Proton Beam
Therapy Initiation in Achieving Complete Response in Pediatric
Medulloblastoma: A Retrospective Study.
Cancer
Med. 2026 Mar 31;15(4):e71757. doi:
10.1002/cam4.71757. PMID:
41916720. ˍ